The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Official Title: Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Study ID: NCT00895674
Brief Summary: Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When this study has been started the standard therapy for patients has been cytokines, which might be accompanied by significant toxicities or might fail the therapeutic goal. In these cases sorafenib can be a feasible therapeutic option. This non-interventional study has been created and is being conducted to collect clinical data on the patients' therapy with sorafenib in an everyday treatment schedule. The main goal of this study focuses on patient characteristics and tumor status in RCC treated with sorafenib as well as the treatment duration and safety of sorafenib under everyday treatment conditions.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Many Locations, , Argentina
, Many Locations, , Austria
, Many Locations, , China
, Many Locations, , Colombia
, Many Locations, , Czech Republic
, Many Locations, , France
, Many Locations, , Germany
, Many Locations, , Greece
, Many Locations, , Indonesia
, Many Locations, , Korea, Republic of
, Many Locations, , Mexico
, Many Locations, , Netherlands
, Many Locations, , Philippines
, Many Locations, , Poland
, Many Locations, , Russian Federation
, Many Locations, , Slovakia
, Many Locations, , Slovenia
, Many Locations, , Sweden
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR